Effects of coenzyme Q$_{10}$ supplementation on oxidative stress markers, inflammatory markers, lymphocyte subpopulations, and clinical status in dogs with myxomatous mitral valve diseaseDruzhaeva, Natalia (Avtor) Nemec Svete, Alenka (Avtor) Tavčar-Kalcher, Gabrijela (Avtor) Babič, Janja (Avtor) Ihan, Alojz (Avtor) Pohar, Katka (Avtor) Krapež, Uroš (Avtor) Domanjko-Petrič, Aleksandra (Avtor) coenzyme Q$_{10}$ubiquinonesupplementationmyxomatous mitral valve diseasecongestive heart failuredogoxidative stressinflammationlymphocytesneutrophilscoenzymesheart failureScarce data exist on the effects of coenzyme Q$_{10}$ (CoQ$_{10}$) supplementation in dogs with myxomatous mitral valve disease (MMVD). The purpose of this study was to investigate the effect of CoQ$_{10}$ supplementation on oxidative stress markers (glutathione peroxidase, F2-isoprostanes), markers of inflammation (tumor necrosis factor-α, TNF soluble receptor II, leucocytes, and their subtypes), lymphocyte subpopulations (T helper and cytotoxic T lymphocytes, including activated T lymphocytes, and B lymphocytes), and echocardiographic and clinical parameters in dogs with MMVD. In this randomized, controlled, double-blind, longitudinal study, 43 MMVD dogs in stages ACVIM (American College of Veterinary Internal Medicine classification) B2 and ACVIM C and D (congestive heart failure (CHF)) received water-soluble coenzyme Q$_{10}$ (100 mg twice daily) or placebo for 3 months, and 12 non-supplemented healthy dogs served as controls. All parameters were measured before and after supplementation in MMVD dogs and once in healthy dogs. CoQ$_{10}$ supplementation had a positive impact on neutrophil percentage, lymphocyte percentage, and lymphocyte concentration in our cohort of dogs with CHF (ACVIM C and D). Conclusion: CoQ$_{10}$ as an oral supplement may have benefits in terms of decreasing inflammation in dogs with MMVD and CHF.20222022-08-02 10:25:42Članek v reviji138596sl